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Abstract
Objective: The Global FKRP Registry is a database for individuals with condi-
tions caused by mutations in the Fukutin-Related Protein (FKRP) gene: limb
girdle muscular dystrophy R9 (LGMDR9, formerly LGMD2I) and congenital
muscular dystrophies MDC1C, Muscle–Eye–Brain Disease and Walker–Warburg
Syndrome. The registry seeks to further understand the natural history and
prevalence of FKRP-related conditions; aid the rapid identification of eligible
patients for clinical studies; and provide a source of information to clinical and
academic communities. Methods: Registration is patient-initiated through a
secure online portal. Data, reported by both patients and their clinicians,
include: age of onset, presenting symptoms, family history, motor function and
muscle strength, respiratory and cardiac function, medication, quality of life
and pain. Results: Of 663 registered participants, 305 were genetically con-
firmed LGMDR9 patients from 23 countries. A majority of LGMDR9 patients
carried the common mutation c.826C > A on one or both alleles; 67.9% were
homozygous and 28.5% were compound heterozygous for this mutation. The
mean ages of symptom onset and disease diagnosis were higher in individuals
homozygous for c.826C > A compared with individuals heterozygous for
c.826C > A. This divergence was replicated in ages of loss of running ability,
wheelchair-dependence and ventilation assistance; consistent with the milder
phenotype associated with individuals homozygous for c.826C > A. In
LGMDR9 patients, 75.1% were currently ambulant and 24.6%, nonambulant
(unreported in 0.3%). Cardiac impairment was reported in 23.2% (30/129).
Interpretation: The Global FKRP Registry enables the collection of patient nat-
ural history data, which informs academics, healthcare professionals and indus-
try. It represents a trial-ready cohort of individuals and is centrally placed to
facilitate recruitment to clinical studies.
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Introduction
In recent years, advances in potential treatments for rare
neuromuscular disorders have gained pace with the devel-
opment of multiple molecular therapies. In conjunction
with these developments, the relevance and importance of
patient registries as a tool to assist patient location and
recruitment have become firmly established.
The Global FKRP Registry collects clinical and genetic
data from individuals with mutations in the Fukutin-
Related Protein (FKRP) gene. FKRP mutations cause a
number of rare, autosomal recessive muscular dystrophies
(MDs), the most common of which is limb girdle muscu-
lar dystrophy R9, FKRP-related (LGMDR9), formerly
named LGMD2I and muscular dystrophy-dystroglycanopa-
thy type C, 5 (MDDGC5) (OMIM#607155). FKRP muta-
tions are also the cause of the rarer congenital conditions
congenital muscular dystrophy type 1C (MDC1C), mus-
cle–eye–brain disease (MEB), and Walker–Warburg syn-
drome (WWS), which present with a more severe
phenotype.1 FKRP-related MDs are highly variable in pre-
sentation, as might be expected when comparing the con-
genital conditions to the later onset LGMDR9. However,
even within LGMDR9, there is considerable variation in
disease onset and progression, ranging from a childhood-
onset, Duchenne-like progression, to mild, adult onset phe-
notypes with preserved walking ability for decades.2,3 There
is currently no curative treatment for FKRP-related MDs,
with many affected individuals losing mobility, requiring
ventilation and cardiac intervention. Steroid treatment may
be an option but until now only case reports have been
published.4–6 Recent research indicates the efficacy of gene
replacement therapy in a murine model,7–10 leading to the
introduction of gene therapy development programmes in
LGMDR9. Encouraging preclinical research in gene
replacement therapy and pluripotent stem cell therapy11
demonstrate the increasing need to prepare for potential
clinical trials and ensure that eligible patient cohorts can
be identified for these novel therapies.
Drug development for rare diseases is associated with
many and specific challenges, including low patient num-
bers available for study, limited knowledge of the disease’s
natural progression and heterogeneity of the disease.
Patient registries help to surmount these challenges by pro-
viding a useful tool to support and facilitate drug develop-
ment and research. In 2011, the Global FKRP Registry was
established to resolve the challenges of data fragmentation
and lack of infrastructure for trial-readiness in FKRP-re-
lated MDs. The rarity of FKRP-related MDs favored the
establishment of an international registry rather than
national registries. The registry provides a source of infor-
mation to assist research, for example, in the identification
of appropriate outcome measures and the understanding
of underlying pathologies; to support healthcare profes-
sionals in the development of standards of care; to dissemi-
nate relevant FKRP-related information and support the
FKRP community. The Global FKRP Registry was created
under the auspices of the TREAT-NMD Alliance.12,13
TREAT-NMD has long championed patient registries,
exemplifying their use in facilitating planning and recruit-
ment for clinical trials for rare inherited neuromuscular
diseases (for example, Duchenne muscular dystrophy
(DMD) and spinal muscular atrophy (SMA)), their suc-
cessful utilization by both researchers and industry, and
their assistance in gaining a better understanding of the
natural history of rare diseases.14–17 As novel therapies pro-
gress to trial and ultimately to market, registries are enter-
ing a new phase in their evolution by their utilization to
capture pharmacovigilance and long-term efficacy data.
This article describes the Global FKRP Registry and the
characteristics of its patient cohort, obtained from the
registry’s inception in April 2011–March 2019. In March
2019, the overall Global FKRP Registry population was
663 participants. Here we provide cross-sectional analysis
on patients with genetically confirmed FKRP-related MD
(n = 320/663) and, more particularly, on the genetically
confirmed LGMDR9 cohort (305).
Subjects and Methods
The Global FKRP Registry is an international, online reg-
istry, accessed at www.fkrp-registry.org, which captures clin-
ical and genetic information entered by both patients and
their nominated clinicians via the same interface (Fig. 1).
Patients initiate registration and provide consent online.
They are then asked to complete a short mandatory ques-
tionnaire about the current status of their health and two
optional validated questionnaires on quality of life
(INQoL18) and pain (McGill19) (copyright for questionnaire
use was obtained). The mandatory dataset for patients was
developed with input from key opinion leaders, genetic cen-
ters, patients, and patient organization representatives, and
focuses on the key items which help to carry out feasibility
studies and recruitment for clinical trials (Table 1).
It is a special feature of the Global FKRP Registry that
during the registration process, patients indicate their respec-
tive neuromuscular specialist from a prepopulated list and
provide consent for that clinician to enter their medical data
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into the registry. The nominated clinicians can view and add
clinical and genetic information for the patients that have
selected them. A yearly information update is requested from
patients and clinicians for longitudinal data capture. This
allows for collection of data over time to provide a more
detailed clinical picture of disease progression with regards
to genotype.
The registry uses bespoke software designed at the Frie-
drich-Baur-Institute of Ludwig-Maximilians-University
Munich. The Java EE-based web application covers both
the patient identity and medical data management by cura-
tors as well as a user-friendly interface for patients and
clinicians. The registry holds favorable ethical opinions
from the “Ethikkommission der Medizinischen Fakult€at
der LMU M€unchen”, for Germany and from the NRES
Committee North East – Newcastle and Tyneside 1, for the
United Kingdom (UK). A steering committee, including
neuromuscular specialists, geneticists and patient represen-
tatives, oversees governance of the registry and ensures that
all enquiries are in line with its purpose and in the best
interests of the patients. All requests into the registry from
third parties are considered and must be approved by the
steering committee. Only anonymous and aggregate infor-
mation on patients in the registry is shared with third par-
ties. Recruitment into clinical trials is implemented by the
registry curator who identifies and contacts potentially
eligible patients, effectively ensuring that pharmaceutical
companies never receive patient contact details directly.
Statistical analysis was performed using SPSS software.
Results
Patient demographics
Six hundred and sixty-three patients with FKRP-related
MDs worldwide registered with the Global FKRP Registry
between April 2011 and March 2019. The largest cohort of
patients reported a diagnosis of LGMDR9 (586, 88.4%). A
further 2.0% (13) reported a diagnosis of MDC1C and
4.1% (27) of an unspecified FKRP-related MD. A diagnosis
was not reported in 5.5% (37) registrations. Genetic confir-
mation was pending for a proportion of patients due to a
number of factors including restricted availability of genetic
testing in some countries. In its absence, it was not possi-
ble for the registry to confirm that a patient has an FKRP-
related condition. Therefore, only data from patients with
confirmed FKRP mutation are here presented.
Three hundred and twenty registry participants had
genetic confirmation of their FKRP-related MD, of which
305 (95.3%; 168 female, 137 male) were diagnosed with
LGMDR9 and 15 (4.9%; 9 female, 6 male), with another
form of FKRP-related MD. Genetically confirmed patients
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Figure 1. Registration process and data flow in the Global FKRP Registry.
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originated from 23 countries, the majority of whom were
from Germany (96; 30.0%); United States of America
(USA, 69; 21.6%); UK (50; 15.6%); and Denmark (31;
9.7%). The age range of genetically confirmed patients
was normally distributed and the largest number of
patients were between 10 and 59 years of age (Fig. 2).
Our descriptive analyses focus on the 305 patients with
genetically verified diagnosis of LGMDR9.
Genetic mutations
A large variety of genetic mutations in the FKRP gene was
reported in the registry. A majority of LGMDR9 patients
was homozygous for the common mutation (c.826C > A;
207, 67.9%), followed by compound heterozygosity for the
common mutation (87, 28.5%) and compound heterozy-
gosity for mutations other than c.826C > A (8, 2.6%).
Three patients were homozygous for a mutation other than
c.826C > A (1.0%) (Table S1). Patients who did not pos-
sess the c.826C > A mutation were from Australia (1),
Canada (4), France (1), Germany (1), Spain (1), Sweden
(1), and the USA (2). Among the compound heterozygous
mutations, the most frequently found on the second allele
were c.919T > A (4), c.1384C > T (4), c.1073C > T (4),
and c.586G > C (4). The age distribution of LGMDR9
patients with at least one allele of the common mutation is
described (Fig. 3). Patients homozygous for the common
allele had a relatively normal age distribution with greatest
numbers between the ages of 30 and 59 years. In contrast,
in individuals heterozygous for the common mutation, the
distribution curve was shifted to the left, with greatest
numbers occurring between the ages of 10 and 29 years,
and group mean ages were significantly different
(P < 0.0001), indicative of the patient cohort being affected
by greater disease severity. There are 30 novel mutations
associated with a disease phenotype reported in the registry,
which have not previously been reported in the Leiden
Open-source Variation Database (LOVD) or in ClinVar.
Disease onset, diagnosis and presenting
symptoms in LGMDR9
In LGMDR9 patients, the mean age when symptoms first
presented, or were incidentally found, was 15.1  12.3 years
(152 patients). However, patients with the homozygous com-
mon mutation (102) appeared to present at the mean age of
19.0  12.4 years, a range of 7.0–13.2 years later than
patients who carried at least one disease allele different from
the common mutation (P < 0.0001) (Table S2). Age of dis-
ease onset was reported by clinicians and was therefore not
available for all patient records analyzed. The most frequently
reported presenting symptoms were weakness in lower limbs
(107), proximal weakness (69) and hyperCKaemia (52). The
mean age of disease onset for each of these symptoms was
17.2  12.8, 18.1  12.6 and 11.0  8.8 years, respectively.
LGMDR9 individuals who were homozygous for the com-
mon mutation presented later than average for these symp-
toms, consistent with their presentation with a milder
phenotype. Of the patients presenting with hyperCKaemia,
29 patients had the homozygous common mutation, 19 were
heterozygous for the common mutation, two patients were
heterozygous, and two were homozygous for a mutation
other than c.826C > A. In this snapshot analysis, the mean
age of diagnosis for all LGMDR9 patients (defined as the age
when a genetic confirmation was received) was
30.1  17.3 years, significantly earlier than for LGMDR9
Table 1. The clinical dataset captured in the Global FKRP Registry.
Patient-reported data Professional-reported data
Demographicsc Disease onset
Diagnosisb Agec
Motor function Symptomsb
Current best motor functiona,* Respiratory function*
Previous best motor functiona FVCb
Wheelchair usea,* Cardiac function*
Myalgia,* Echob
Ventilation* MRI*
Noninvasivea Brainb
Invasivea Muscleb
Family historya Cognitive functiona
Quality of life (INQoL)a,* Contracturesb,*
McGill Pain Questionnaire (SF-
MPQ)a,*
Other medical problemsb
Current medicationb
Muscle strength and
function*
6MWDc
MRC scoresc
Genetic mutationb
Data are defined as being either patient-reported or professional-re-
ported and data items collected longitudinally are labeled with *. The
reporting options available for each data item are indicated: adrop-
down menu only; bdrop-down menu with option to add additional
information as free text; and cfree text only. Among all registry partic-
ipants, completion of patient-reported data items ranges between 87
and 95%. Completion rates of INQoL and SF-MPQ are approximately
75%. A doctor has been selected by 40% (267/663) of all registry
participants, 42% (111/267) of whom have entered data on behalf of
their patient. Participation is increased among patients with genetic
confirmation of FKRP mutation: completion of patient-reported data
items ranges between 98 and 100%. Completion rates of INQoL and
SF-MPQ are approximately 95%. A doctor has been selected by 56%
(180/320) of genetically confirmed participants, 58% (105/180) of
whom have entered data on behalf of their patient. Medical patient
records are the source of professional-reported data. When consider-
ing family history, patients are asked only whether a family member
has been diagnosed with an FKRP-related condition. Therefore, with
the exception of child siblings registered by the same parent/guardian,
family links between registry participants are not readily available.
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patients with the homozygous common mutation whose
mean age of diagnosis was 34.8  15.9 years (P = 0.005).
This followed the trend for later disease onset in this patient
cohort.
Motor function
The registry collected data on both the previous best
motor function and the current motor function of
patients. The classification of motor function was divided
into ambulant (run, climb stairs with/out assistance, walk
with/out assistance) and nonambulant (sit independently,
neither able to sit nor walk independently). Among genet-
ically confirmed LGMDR9 patients, 303 (99.3%) reported
having been ambulant at some stage in their life. Two
hundred and twenty-nine (75.1%) LGMDR9 patients
were currently ambulant and 75 (24.6%) were nonambu-
lant (unreported by one individual (0.3%)). Though
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Figure 2. The current age of all genetically confirmed Global FKRP Registry participants (n = 320). The number of male and female patients
within each 10-year age range, from 1 to 9 through to 70–79 years, is presented. Male (black); female (gray).
0
5
10
15
20
25
30
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79
N
um
be
r o
f p
at
ie
nt
s
Age range, years
Figure 3. The current age of LGMDR9 patients with the common FKRP gene mutation (c.826C > A, n = 294). Patient number within each 10-
year age range is further stratified by zygosity of the common FKRP gene mutation and by sex. The difference between homozygous c.826C > A
and heterozygous c.826C > A mean ages is significant (P < 0.0001). Homozygous c.826C > A, male (black); Homozygous c.826C > A, female
(gray); Heterozygous c.826C > A, male (white); Heterozygous c.826C > A, female (dots).
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captured by the registry and reported by the majority of
patients, longitudinal data were not considered in this
analysis and snapshot analyses of current data only are
here presented.
Previous best motor function
Analysis of the previous best motor function indicated
that the majority of genetically confirmed LGMDR9
patients (234/305, 76.7%) were able to run in the past.
This ability was achieved in an equal proportion of
patients homozygous and compound heterozygous for the
common mutation (80.6%, 166/206 vs. 70.1%, 61/87,
P = 0.059). In both genotype groups, the ability to run
diminished and was lost in the first few decades of life
with the majority having lost it by the age of 40–49 years
(Fig. 4A). Within the group, loss of running ability by
individuals compound heterozygous for the common
mutation occurred earlier than in individuals homozygous
for the common mutation (average age of
15.9  10.2 years compared with 26.2  10.7 years,
respectively, P < 0.0001). By the age of 29 years, 91.8% of
the group compound heterozygous for the common
mutation had lost their ability to run. In homozygous
females, running ability was lost earlier than in their male
counterparts, with 70.4% of females losing this ability
before the age of 29 years compared with 50.9% of males
(P = 0.027). Phenotypic differences between the sexes
have previously been reported20 though not a difference
in disease severity. Within patient-reported data, elements
of bias in patient selection, reporting and recall may
occur that impact on the collective dataset. Though its
potential influence may be difficult to identify, it should
be acknowledged.
Current motor function – ambulation in LGMDR9
Analysis of the current motor function showed a general
trend of older patients being less mobile, mirroring the
trend within the wider, healthy population.
Cross-sectional analysis of genetically confirmed
LGMDR9 registry participants indicated that 42/304
(13.8%) were currently able to run: 28 (9.2%) with the
homozygous common mutation (age < 39 years); 13
(4.3%) with the heterozygous common mutation
(age < 25 years); and one (0.3%) with a heterozygous
unique mutation (age = 12 years). This further suggests
that patients with compound heterozygous mutations
showed a more rapid disease progression, expressed as
mobility challenges earlier in life.
One hundred and eighty-seven (61.5%) LGMDR9
patients reported that they were currently able to climb
stairs or walk with or without support, the oldest of
whom was 76 years old. This cohort included 141
(46.4%) patients with the homozygous common muta-
tion, 40 (13.1%) with one common mutation, three
patients (1.0%) with unique homozygous, and three
(1.0%) with unique heterozygous mutations. The mean
age of patients with homozygous common mutation with
preserved ability to climb stairs (59/141) was
43.5  14.6 years. As anticipated, this was lower than the
mean age of patients of this mutation type whose current
best motor function was walking (82/141;
47.0  13.4 years). The mean age of patients with one
common mutation who were able to climb stairs (15/40)
was 25.5  16.9 years compared with that of those able
to walk (25/40), which was 37.2  18.7 years. These data
indicate that individuals with a single common mutation
lose their ability to climb stairs (P < 0.0001) and walk
(P = 0.005) at an earlier age than those with two com-
mon mutations. The current ambulatory status of
LGMDR9 patients with the common mutation is summa-
rized in Figure 4B.
Current motor function – loss of ambulation in
LGMDR9
Among LGMDR9 patients with the homozygous common
mutation, 92/207 (44.4%) were wheelchair-dependent
(full-time 38/92, mean age 53.2  12.7 years; part-time
54/92, mean age 45.8  15.8 years). Among patients who
were heterozygous for the common mutation, 56/87
(64.4%) were wheelchair-dependent (full-time 35/56,
mean age 32.6  12.0 years; part-time 21/56, mean age
25.4  13.6 years) (Fig. 4c). Comparison between each
patient group shows significant differences in mean age of
part-time wheelchair users (P < 0.0001) and full-time
wheelchair users (P < 0.0001).Once again, this underlines
the faster disease progression in heterozygous patients
who became wheelchair-dependent earlier in life in com-
parison with homozygous patients.
Ventilation
Breathing complications are common in FKRP-related
MDs. Therefore, the registry collected data on the respira-
tory impairment of patients and their use of assisted ven-
tilation.
Noninvasive ventilation
Within the genetically confirmed LGMDR9 patient
cohort, 46 patients (15.1%) used noninvasive ventilation,
39 (12.9%) of whom reported the age at which they
began respiratory support. The average age of starting
noninvasive ventilation was 40.8  15.0 years, with
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Figure 4. The age of LGMDR9 patients with the common FKRP gene mutation associated with specific motor functions: (A) the age of LGMDR9
patients at which running ability was lost (n = 171). The difference between homozygous c.826C > A and heterozygous c.826C > A mean ages
is significant (P < 0.0001); (B) the current age of ambulant LGMDR9 patients (n = 222); and (C) the current age of LGMDR9 patients who use a
wheelchair, either part-time or full-time (n = 148). For each graph, patient number within each 10-year age range is further stratified by zygosity
of the common FKRP gene mutation and by sex. Homozygous c.826C > A, male (black); Homozygous c.826C > A, female (gray); Heterozygous
c.826C > A, male (white); Heterozygous c.826C > A, female (dots).
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differences between the genotypes. In the group com-
pound heterozygous for the common mutation, respira-
tory function appeared to be impaired earlier in life, with
a mean age of starting noninvasive ventilation of
32.7  13.2 years (12 patients) compared with the
patients homozygous for the common mutation whose
equivalent mean age was 46.6  13.7 years (24 patients,
P = 0.006) (Table S2).
Invasive ventilation
Nine patients (2.9%) reported receipt of invasive ventila-
tion with the mean age of commencement being
43.1  10.3 years (age reported by six patients). The
heterozygous common mutation patient population
started invasive ventilation at an earlier mean age of
39.3  5.0 years (5 patients). In comparison, only one
patient homozygous for the common mutation started
invasive ventilation, aged 62 years.
Cardiac function
Within the registry, information about patients’ cardiac
function was provided by clinicians. There was information
about cardiac function for 129/305 genetically confirmed
LGMDR9 patients in the registry, of whom 82 (63.6%)
showed normal results at their last cardiac assessment and
30 (23.2%) showed some cardiac impairment. Cardiac
function was not specified for 17 patients (13.2%) as these
records were unavailable to the reporting clinician. Further
breakdown indicated that, of 30 individuals with impaired
cardiac function, 18 had started treatment, two showed
cardiac deterioration and had their medication changed as
a result, and 10 were not on treatment. Of the 129
LGMDR9 patients for whom cardiac information was
available, 29 (22.5%) individuals took ACE inhibitors and
16 (12.4%) were prescribed beta blockers.
Discussion
The Global FKRP Registry captures a wealth of data,
including patients’ current disease status and their longitu-
dinal history. The registry holds data reported by both
patients and clinicians, which enhances its validity and
helps reduce the requirement for lengthy curation time,
often required by registries that capture patient-entered data
only. This combined reporting method enables patients to
drive the process and register themselves while also ensur-
ing the capture of high quality data. Patients are able to act
as a catalyst to prompt their clinician if data are not
entered.
The Global FKRP Registry is currently available in Eng-
lish, German, Norwegian, and Portuguese. This limited
availability of languages may present a barrier to registra-
tion for some patients. Furthermore, the registry’s name,
the Global FKRP Registry, may not be immediately recog-
nizable to patients, as it includes the name of the causa-
tive gene rather than those of the associated diseases.
Unless directed by their clinician, many patients will not
initially know that their condition is caused by a muta-
tion in the FKRP gene. Patient awareness is therefore still
a substantial challenge for the registry in terms of patient
recruitment. This is addressed by presenting the registry
at various scientific and patient conferences, by patient
organizations emphasizing the value of the registry in
LGMDR9-specific social media groups and through direct
communication.
Worldwide, clinicians have limited time available to
enter patient data, therefore, obtaining complete datasets
is challenging. To facilitate this process, the steering com-
mittee has reviewed and amended the mandatory ques-
tionnaires for both patients and clinicians to maximize
the data that can be entered by patients and capitalize on
their motivation. As genetic information is reported by
clinicians, it is difficult to ensure that all patients do
indeed have an FKRP-related MD at the time of registra-
tion. Encouraging patients to send their own genetic
report directly to the registry both reduces this burden
from clinicians and curation time.
The analysis of clinical and genetic data from the Glo-
bal FKRP Registry has demonstrated that LGMDR9
patients who are homozygous for the common mutation
(c.826C > A) are more likely to have a milder phenotype
and have a later disease onset than those patients who are
compound heterozygous for the common mutation, or
have a mutation other than the common mutation.
Grouping of the data by the presence or absence of the
common mutation may be a generalization but reflects
broad phenotypic observations of the LGMDR9 cohort
and paves the way for more detailed investigation of the
association between FKRP gene mutation and disease
phenotype. It is important to bear in mind that the con-
genital FKRP-related MDs are underrepresented in the
registry due to their severity and early onset. This con-
tributed to the selection of LGMDR9 alone as the focus
of this article.
Analysis of the registry data indicates that disease
symptoms presented on average between 7.0 and
13.2 years later in patients with LGMDR9 who were
homozygous for the common mutation; with weakness in
lower limbs, proximal weakness and hyperCKaemia being
the most common presenting symptoms and affecting
more than 30% of all genetically confirmed LGMDR9
patients. The average age of disease diagnosis was
30.1  17.3 years. This varied depending on the causative
genetic mutation, with patients who were homozygous
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for the common mutation being diagnosed around
4.5 years later (34.8  15.9 years).
The walking ability of patients was variable across the
range of ages, with no specific, well-defined period at
which there was a greater probability of becoming non-
ambulant. LGMDR9 patients tended to retain the ability
to walk into their fifties, even into their seventies. How-
ever, in this analysis of current data only, it was not pos-
sible to determine the exact age at which loss of
ambulation occurred. Past best and current motor func-
tions and the age at which they were gained/lost are
reported by patients on an annual basis. Therefore, data
enabling the rate of disease progression to be studied are
potentially captured, however, they are not included in
this analysis. In addition, greater granularity in question-
naire answers would allow a more accurate prediction of
the course of disease progression.
Fifty-five genetically confirmed LGMDR9 patients (55/
303, 18.2%) included in this snapshot analysis required
ventilation, both noninvasive (46/303; 15.2%) and inva-
sive (9/303; 3.0%), and 30/129 (23.3%) reported a heart
condition. This demonstrates the importance of monitor-
ing both pulmonary and cardiac function as routine
aspects of care for the FKRP-related MDs. It is recognized
that LGMDR9 may sometimes follow the presentation of
DMD. Therefore, the care standards for DMD21,22 should
be followed, which include monitoring heart and lung
function to enable intervention before significant deterio-
ration occurs, as is the same with the congenital muscular
dystrophies.23,24 Further analysis with greater numbers of
patients may allow predictions of which subpopulations
are at greater risk of developing heart and/or lung com-
plications, based on their specific genetic mutations.
Recent advances in neuromuscular disease-specific ther-
apies, spearheaded by novel gene therapy developments in
DMD and SMA, reflect the current excitement and opti-
mism within the field. For LGMDR9, the Global FKRP
Registry has facilitated recruitment to a number of natu-
ral history and research studies and clinical trials. How-
ever, the development of new therapies introduces the
new challenge of capturing postmarketing surveillance
data, a task the registry is well placed to accommodate. It
is intended that presentation of this snapshot analysis of
LGMDR9 will add to the growing body of knowledge of
the condition and support the establishment of bespoke
LGMD standards of care.
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